Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Application
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

AM630 binds selectively to cannabinoid 2 (CB2) over CB1 receptors with Ki values of 31.2 and 5,152 nM, respectively.1 AM630 acts as an inverse agonist at CB2 receptors, attenuating the antinociceptive effects of a number of cannabinoids, and as a weak partial agonist at CB1 receptors.1,2,3 It decreases proliferation and induces arrest of the cell cycle at the G2/M phase in renal cell carcinoma cells.4
WARNING This product is not for human or veterinary use.
1. Agonist-
2. CB2 cannabinoid receptor-
3. Development of a potent inhibitor of 2-
4. Cannabinoid receptor 2 as a novel target for promotion of renal cell carcinoma prognosis and progression. J. Cancer Res. Clin. Oncol. (2017).
Cannabinoid WIN 55,212-
Anti-
Involvement of ERK1/2, cPLA2 and NF-
R-